Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin®) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport®)

J Neurol Sci. 2015 Mar 15;350(1-2):110-1. doi: 10.1016/j.jns.2015.01.032. Epub 2015 Jan 29.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Autoantibodies / adverse effects*
  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / adverse effects*
  • Dystonic Disorders / diagnosis
  • Dystonic Disorders / drug therapy*
  • Female
  • Humans
  • Middle Aged
  • Treatment Failure
  • Treatment Outcome

Substances

  • Autoantibodies
  • Botulinum Toxins, Type A
  • abobotulinumtoxinA
  • incobotulinumtoxinA